title: Influence of severity of chronic inflammatory joint disease on the pharmacokinetics of indomethacin and etodolac.
abstract: The goal of this study was to look for correlations between the severity of chronic inflammatory joint disease and pharmacokinetic parameters of nonsteroidal antiinflammatory drugs. Disease severity data (pain severity and magnitude of abnormalities in laboratory tests for inflammation) and pharmacokinetic data (area under the curve in the morning (AUCm) and maximum plasma concentration (Cmax) were collected during a prospective, randomized, double-blind, parallel-group study. Two groups of nine and 11 patients, respectively, were given 300 mg etodolac b.i.d or 50 mg indomethacin b.i.d. by the oral route, for three days, after a 36-hour placebo washout. Univariate analyses demonstrated statistically significant negative correlations between pharmacokinetic parameters of both study drugs and a number of disease severity parameters. In the multivariate analysis of data for etodolac, the sigma erythrocyte sedimentation rate contributed significantly to variations in all pharmacokinetic parameters and explained 100% of the variations in free S-enantiomer AUCm and in total and free S-enantiomer Cmax. For indomethacin, pain contributed to variations in Cmax values of the total and free forms; the sigma erythrocyte sedimentation rate was also a factor in variations in total indomethacin. These negative correlations suggest that severity of chronic inflammatory joint disease may influence the pharmacokinetics of nonsteroidal antiinflammatory drugs.
authors.affiliation: Rheumatology Department, Rennes Teaching Hospital, France.
authors.forename: Y
authors.initials: Y
authors.lastname: Pawlotsky
authors.forename: P
authors.initials: P
authors.lastname: Le Dantec
authors.forename: C
authors.initials: C
authors.lastname: Jacquelinet
authors.forename: F
authors.initials: F
authors.lastname: Lapicque
authors.forename: J
authors.initials: J
authors.lastname: Goasguen
authors.forename: A
authors.initials: A
authors.lastname: Perdriger
authors.forename: E
authors.initials: E
authors.lastname: Veillard
authors.forename: P
authors.initials: P
authors.lastname: Guggenbuhl
authors.forename: P
authors.initials: P
authors.lastname: Netter
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D019540:Area Under Curve; D002908:Chronic Disease; D004311:Double-Blind Method; D017308:Etodolac / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007213:Indomethacin / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D007249:Inflammation / Q000188:drug therapy / Q000503:physiopathology; D007592:Joint Diseases / Q000188:drug therapy* / Q000503:physiopathology; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012720:Severity of Illness Index
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D017308:Etodolac; D007213:Indomethacin